Impact of Evidence-Based Stroke Care on Patient Outcomes: A Multilevel Analysis of an International Study

J Am Heart Assoc. 2019 Jul 2;8(13):e012640. doi: 10.1161/JAHA.119.012640. Epub 2019 Jun 25.

Abstract

Background The uptake of proven stroke treatments varies widely. We aimed to determine the association of evidence-based processes of care for acute ischemic stroke ( AIS ) and clinical outcome of patients who participated in the HEADPOST (Head Positioning in Acute Stroke Trial), a multicenter cluster crossover trial of lying flat versus sitting up, head positioning in acute stroke. Methods and Results Use of 8 AIS processes of care were considered: reperfusion therapy in eligible patients; acute stroke unit care; antihypertensive, antiplatelet, statin, and anticoagulation for atrial fibrillation; dysphagia assessment; and physiotherapist review. Hierarchical, mixed, logistic regression models were performed to determine associations with good outcome (modified Rankin Scale scores 0-2) at 90 days, adjusted for patient and hospital variables. Among 9485 patients with AIS, implementation of all processes of care in eligible patients, or "defect-free" care, was associated with improved outcome (odds ratio, 1.40; 95% CI, 1.18-1.65) and better survival (odds ratio, 2.23; 95% CI , 1.62-3.09). Defect-free stroke care was also significantly associated with excellent outcome (modified Rankin Scale score 0-1) (odds ratio, 1.22; 95% CI , 1.04-1.43). No hospital characteristic was independently predictive of outcome. Only 1445 (15%) of eligible patients with AIS received all processes of care, with significant regional variations in overall and individual rates. Conclusions Use of evidence-based care is associated with improved clinical outcome in AIS . Strategies are required to address regional variation in the use of proven AIS treatments. Clinical Trial Registration URL : https://www.clinicaltrials.gov . Unique Identifier: NCT02162017.

Keywords: acute stroke care; multilevel analysis; outcome; quality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy
  • Australia
  • Brain Ischemia / physiopathology
  • Brain Ischemia / therapy*
  • China
  • Deglutition Disorders / diagnosis
  • Evidence-Based Medicine*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • India
  • Logistic Models
  • Male
  • Middle Aged
  • Multilevel Analysis
  • Outcome and Process Assessment, Health Care*
  • Patient Positioning
  • Physical Therapy Modalities / statistics & numerical data
  • Platelet Aggregation Inhibitors / therapeutic use
  • South America
  • Sri Lanka
  • Stroke / etiology
  • Stroke / physiopathology
  • Stroke / therapy*
  • Taiwan
  • Thrombectomy / statistics & numerical data
  • Thrombolytic Therapy / statistics & numerical data
  • United Kingdom

Substances

  • Anticoagulants
  • Antihypertensive Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors

Associated data

  • ClinicalTrials.gov/NCT02162017